Stock listing
TPEx:6586 CHO Pharma, Inc. (醣基) 股價
Follow CHO Pharma, Inc. into a list and get an email when it puts out news.
Share price · TPEX:6586
$63.70 TWD -8.50 (-11.8%)
Close on Nov 20, 2026
- Day range
- $62.00 – $72.80 TWDNov 20, 2026
- Volume
- 789,967 sharesNov 20, 2026
- Market cap
- $13.63B TWDAt the close on Nov 20, 2026 · price × 214.0M shares outstanding
- 52-week range
- $22.75 – $148.50 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $49.66M TWDMedian day 394,061 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:6586 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $63.70 | -8.50 | -11.8% | $72.80 | $72.80 | $62.00 | 789,967 | |
| $72.20 | -7.60 | -9.5% | $80.60 | $80.60 | $71.30 | 458,210 | |
| $79.80 | -4.20 | -5.0% | $85.50 | $85.80 | $77.90 | 394,061 | |
| $84.00 | -5.70 | -6.4% | $89.80 | $92.30 | $82.70 | 648,505 | |
| $89.70 | +13.10 | +17.1% | $76.60 | $97.00 | $76.60 | 1,379,124 | |
| $76.60 | +1.40 | +1.9% | $76.90 | $76.90 | $73.80 | 329,746 | |
| $75.20 | -0.80 | -1.1% | $77.00 | $77.60 | $73.90 | 440,053 | |
| $76.00 | +0.80 | +1.1% | $75.00 | $80.60 | $73.00 | 392,259 | |
| $75.20 | 0.00 | 0.0% | $75.70 | $76.50 | $70.10 | 421,357 | |
| $75.20 | +0.50 | +0.7% | $74.30 | $80.50 | $73.10 | 464,821 | |
| $74.70 | -3.50 | -4.5% | $75.00 | $81.60 | $61.80 | 1,074,637 | |
| $78.20 | -10.10 | -11.4% | $88.50 | $89.60 | $76.80 | 600,485 | |
| $88.30 | -2.00 | -2.2% | $89.00 | $91.50 | $84.20 | 500,883 | |
| $90.30 | -8.00 | -8.1% | $98.30 | $98.90 | $85.20 | 1,031,247 | |
| $98.30 | -1.20 | -1.2% | $100.00 | $100.50 | $97.70 | 429,007 | |
| $99.50 | -4.00 | -3.9% | $101.50 | $103.00 | $99.00 | 501,685 | |
| $103.50 | 0.00 | 0.0% | $104.50 | $104.50 | $101.50 | 179,187 | |
| $103.50 | 0.00 | 0.0% | $106.00 | $109.00 | $102.50 | 284,778 | |
| $103.50 | -2.50 | -2.4% | $108.00 | $108.00 | $103.00 | 306,765 | |
| $106.00 | 0.00 | 0.0% | $106.00 | $106.00 | $106.00 | 0 | |
| $106.00 | -8.50 | -7.4% | $114.00 | $114.00 | $105.00 | 560,735 | |
| $114.50 | +10.00 | +9.6% | $106.00 | $118.50 | $105.50 | 766,669 | |
| $104.50 | +0.50 | +0.5% | $104.00 | $105.50 | $102.50 | 165,653 | |
| $104.00 | -3.00 | -2.8% | $107.50 | $108.00 | $102.00 | 193,943 | |
| $107.00 | +1.50 | +1.4% | $107.50 | $108.00 | $105.00 | 108,777 | |
| $105.50 | -2.00 | -1.9% | $108.00 | $108.50 | $104.50 | 262,973 | |
| $107.50 | -2.50 | -2.3% | $108.00 | $112.00 | $106.50 | 274,129 | |
| $110.00 | -4.50 | -3.9% | $112.00 | $114.50 | $108.00 | 411,606 | |
| $114.50 | -0.50 | -0.4% | $115.50 | $116.00 | $112.50 | 251,836 | |
| $115.00 | +0.50 | +0.4% | $115.50 | $116.00 | $113.50 | 201,608 | |
| $114.50 | -1.50 | -1.3% | $114.50 | $116.50 | $113.50 | 315,111 | |
| $116.00 | -3.50 | -2.9% | $122.00 | $124.50 | $113.50 | 845,447 | |
| $119.50 | +3.50 | +3.0% | $117.50 | $125.50 | $115.50 | 1,080,808 | |
| $116.00 | -0.50 | -0.4% | $115.00 | $120.50 | $113.00 | 503,960 | |
| $116.50 | -4.50 | -3.7% | $120.00 | $121.50 | $115.50 | 837,343 | |
| $121.00 | -4.50 | -3.6% | $124.50 | $127.00 | $120.50 | 815,048 | |
| $125.50 | +21.50 | +20.7% | $104.50 | $131.00 | $104.50 | 2,266,115 | |
| $104.00 | +4.00 | +4.0% | $100.50 | $106.00 | $98.70 | 609,174 | |
| $100.00 | -0.50 | -0.5% | $101.00 | $101.50 | $99.00 | 277,671 | |
| $100.50 | -0.50 | -0.5% | $101.50 | $102.00 | $99.70 | 218,896 | |
| $101.00 | +1.00 | +1.0% | $100.50 | $102.50 | $99.70 | 137,968 | |
| $100.00 | -5.00 | -4.8% | $104.00 | $106.00 | $100.00 | 491,900 | |
| $105.00 | +4.50 | +4.5% | $102.00 | $110.50 | $99.70 | 673,596 | |
| $100.50 | +1.90 | +1.9% | $100.00 | $102.00 | $99.50 | 223,939 | |
| $98.60 | -1.90 | -1.9% | $101.00 | $101.00 | $98.60 | 231,059 | |
| $100.50 | 0.00 | 0.0% | $101.00 | $102.50 | $99.10 | 155,092 | |
| $100.50 | -2.00 | -2.0% | $101.50 | $102.50 | $99.00 | 334,554 | |
| $102.50 | -1.50 | -1.4% | $105.50 | $105.50 | $100.50 | 306,379 | |
| $104.00 | -1.50 | -1.4% | $105.50 | $111.00 | $102.50 | 440,033 | |
| $105.50 | +4.50 | +4.5% | $100.00 | $113.50 | $100.00 | 654,096 | |
| $101.00 | +0.50 | +0.5% | $100.50 | $102.50 | $99.00 | 352,315 | |
| $100.50 | -4.00 | -3.8% | $105.00 | $105.50 | $98.70 | 1,197,051 | |
| $104.50 | -5.00 | -4.6% | $110.50 | $111.50 | $103.50 | 881,843 | |
| $109.50 | -0.50 | -0.5% | $110.00 | $113.00 | $109.00 | 321,377 | |
| $110.00 | 0.00 | 0.0% | $109.00 | $111.50 | $108.50 | 275,349 | |
| $110.00 | +1.00 | +0.9% | $108.50 | $114.00 | $108.00 | 516,933 | |
| $109.00 | +0.50 | +0.5% | $109.00 | $111.50 | $108.50 | 211,202 | |
| $108.50 | -1.50 | -1.4% | $111.50 | $112.00 | $108.50 | 478,247 | |
| $110.00 | -2.00 | -1.8% | $112.00 | $114.00 | $109.50 | 393,553 | |
| $112.00 | -1.00 | -0.9% | $113.00 | $113.00 | $110.50 | 160,801 | |
| $113.00 | +1.50 | +1.3% | $112.00 | $114.00 | $110.50 | 298,066 | |
| $111.50 | +1.00 | +0.9% | $114.50 | $114.50 | $110.50 | 217,075 | |
| $110.50 | -2.00 | -1.8% | $113.00 | $115.00 | $109.50 | 353,638 |
- Ticker
- TPEx:6586
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
CHO Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 8,157× against a median of 15.8×: the highest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $11.67B TWD
- P/E
- Loss
- EV/sales
- 8,157×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.7×
- Gross margin
- 74.5%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CHO Pharma, Inc. · TPEX:6586 | US$413.6M | US$354.2M | n/a | 8,157× | n/a | 5.7× | n/a | 0.0× | n/a |
| Indaptus Therapeutics, Inc. · NASDAQ:INDP | US$433.2M | US$402.6M | n/a | n/a | n/a | 41.9× | n/a | 0.0× | 1.77 |
| LongBio Pharma (Suzhou) Co., Ltd. Class H · HKEX:1779 | US$430.7M | US$402.1M | n/a | n/a | n/a | 20.5× | n/a | 0.0× | n/a |
| Ovid Therapeutics Inc. · NASDAQ:OVID | US$429.7M | US$305.4M | n/a | 210× | n/a | 2.2× | n/a | 0.1× | 1.37 |
| Arvinas, Inc. · NASDAQ:ARVN | US$423.0M | −US$135.0M | n/a | −0.5× | n/a | 0.8× | −3.5% | 0.0× | 1.25 |
| Prothena Corporation plc · NASDAQ:PRTA | US$422.1M | US$157.0M | n/a | 3.0× | n/a | 1.6× | −45.4% | 0.0× | 0.96 |
| TaiMed Biologics Inc. · TPEX:4147 | US$421.4M | US$385.5M | n/a | 20.5× | n/a | 3.8× | −22.4% | 0.1× | n/a |
| Tectonic Therapeutic, Inc. · NASDAQ:TECX | US$413.5M | US$178.9M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.95 |
| Jacobio Pharmaceuticals Group Co., Ltd. · HKEX:1167 | US$401.1M | US$173.5M | n/a | 22.2× | n/a | 2.0× | −272.7% | 0.1× | n/a |
| Candel Therapeutics, Inc. · NASDAQ:CADL | US$395.4M | US$193.8M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 2.03 |
| Ever Supreme Bio Technology Co., Ltd. · TPEX:6712 | US$394.8M | US$362.8M | 27.5× | 11.1× | 23.9× | 4.6× | 43.8% | 0.0× | n/a |
| Median of the others | US$421.7M | US$249.6M | 27.5× | 15.8× | 23.9× | 2.6× | −22.4% | 0.0× | 1.31 |
Team and board
Officers
| Officer | Role |
|---|---|
| Chung-Yi Wu | President, CEO |
Board
| Director | Role |
|---|---|
| Chao-Long Chen | Chairman |
| Chung-Yi Wu | President, CEO |
| Jeng-Jiann Chiu | Independent Director |
| Richard M. Tsai | Director |
| Shuan-Ta Liu | Independent Director |
| Shun-Ling Chen | Director |
| Sung-Liang Yu | Independent Director |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.43M | 3.58M | 0 | 60.0K | 3.57M | 138.0K | 297.0K |
| Cost of revenue | 365.0K | 1.87M | 0 | 1.00K | 211.0K | 71.0K | 119.0K |
| Gross profit | 1.07M | 1.71M | 0 | 59.0K | 3.36M | 67.0K | 178.0K |
| Research and development | 286.9M | 219.1M | 239.4M | 326.1M | 193.5M | 287.9M | 344.6M |
| Selling, general and administrative | 40.1M | 31.9M | 21.5M | 24.9M | 20.3M | 21.7M | 24.7M |
| Operating income | -325.8M | -249.3M | -306.0M | -338.1M | -205.3M | -296.1M | -369.2M |
| Depreciation and amortization | 26.7M | 25.9M | 28.3M | 39.9M | 39.1M | 41.2M | 34.1M |
| EBITDA | -299.1M | -223.4M | -277.7M | -298.2M | -166.3M | -254.8M | -335.1M |
| Interest expense | 406.0K | 679.0K | 77.0K | 301.0K | 576.0K | 775.0K | |
| Income before tax | -290.0M | -212.2M | -306.1M | -338.4M | -205.9M | -296.8M | -358.4M |
| Net income | -290.0M | -212.2M | -306.1M | -338.4M | -205.9M | -296.8M | -358.4M |
| Earnings per share, basic | -1.36 | -0.99 | -1.60 | -1.84 | -1.12 | -1.62 | -1.96 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 52.1M | 21.8M | 203.8M | 505.7M | 778.0M | 986.4M | 1.26B |
| Short-term investments | 2.01B | 2.34B | 2.40B | 538.9M | 538.9M | 538.9M | 538.9M |
| Receivables | 0 | 751.0K | 0 | 0 | 63.0K | ||
| Inventory | 1 | ||||||
| Current assets | 2.12B | 2.42B | 2.64B | 1.08B | 1.34B | 1.55B | 1.82B |
| Total assets | 2.57B | 2.88B | 3.09B | 1.60B | 1.89B | 2.14B | 2.43B |
| Current liabilities | 109.1M | 116.2M | 106.0M | 168.9M | 133.2M | 149.2M | 132.7M |
| Total debt | 11.7M | 25.6M | 38.3M | 29.0M | |||
| Total liabilities | 109.1M | 132.6M | 110.8M | 173.7M | 149.7M | 179.7M | 29.0M |
| Shareholders' equity | 2.46B | 2.75B | 2.98B | 1.43B | 1.74B | 1.96B | 2.26B |
| Shares outstanding | 214.0M | 214.0M | 191.3M | 184.0M | 183.9M | 183.7M | 183.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -279.6M | -217.4M | -291.1M | -249.5M | -193.5M | -248.7M | -266.7M |
| Capital spending | -11.7M | -5.49M | -2.00M | -9.40M | -2.64M | -22.2M | -11.4M |
| Free cash flow | -291.3M | -222.9M | -293.1M | -258.9M | -196.1M | -270.9M | -278.2M |
| Cash from financing | 1.85B | -13.9M | -11.3M | -9.59M | 8.81M | ||
| Change in cash | 30.3M | -182.0M | -301.9M | -272.3M | -208.4M | -278.1M | -276.6M |
Cap table
Built by 6ix from CHO Pharma, Inc.’s releases
- Common shares
- 214,010,500
- Fully diluted
- 214,010,500
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 214,010,500 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 214,010,500 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Chao-Long Chen | Chairman · Since at least Nov 5, 2026 |
| Chung-Yi Wu | President, CEO · Since at least Nov 5, 2026 |
| Jeng-Jiann Chiu | Independent Director · Since at least Nov 5, 2026 |
| Richard M. Tsai | Director · Since at least Nov 5, 2026 |
| Shuan-Ta Liu | Independent Director · Since at least Nov 5, 2026 |
| Shun-Ling Chen | Director · Since at least Nov 5, 2026 |
| Sung-Liang Yu | Independent Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about CHO Pharma, Inc.